Generation Bio CoNASDAQ:GBIO
- LAST PRICE2.1800
- TODAY'S CHANGE (%)-0.1700 (-7.2340%)
- Bid / Lots2.0100/ 1
- Ask / Lots2.5000/ 1
- Open / Previous Close2.3600 / 2.3500
- Day Range
- 52 Week Range
- Volume90,181
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GBIO |
|---|---|---|
| 09:32 ET | 342 | 2.36 |
| 09:34 ET | 448 | 2.35 |
| 09:41 ET | 300 | 2.34 |
| 09:48 ET | 100 | 2.33 |
| 09:50 ET | 599 | 2.315 |
| 09:52 ET | 200 | 2.315 |
| 09:54 ET | 100 | 2.315 |
| 09:57 ET | 100 | 2.315 |
| 10:03 ET | 975 | 2.31 |
| 10:08 ET | 1500 | 2.3 |
| 10:12 ET | 300 | 2.3 |
| 10:14 ET | 400 | 2.335 |
| 10:15 ET | 796 | 2.335 |
| 10:17 ET | 100 | 2.35 |
| 10:19 ET | 6139 | 2.34 |
| 10:21 ET | 11534 | 2.34 |
| 10:26 ET | 982 | 2.33 |
| 10:30 ET | 100 | 2.34 |
| 10:35 ET | 1233 | 2.315 |
| 10:37 ET | 500 | 2.33 |
| 10:39 ET | 100 | 2.32 |
| 10:42 ET | 900 | 2.31 |
| 10:46 ET | 421 | 2.3 |
| 10:51 ET | 100 | 2.31 |
| 11:04 ET | 1000 | 2.29 |
| 11:11 ET | 100 | 2.3 |
| 11:22 ET | 728 | 2.295 |
| 11:24 ET | 300 | 2.3 |
| 11:27 ET | 100 | 2.31 |
| 11:33 ET | 410 | 2.31 |
| 11:40 ET | 3000 | 2.3 |
| 11:44 ET | 100 | 2.32 |
| 11:51 ET | 500 | 2.3 |
| 11:54 ET | 2040 | 2.3134 |
| 12:02 ET | 100 | 2.32 |
| 12:20 ET | 400 | 2.3 |
| 12:23 ET | 300 | 2.31 |
| 12:25 ET | 592 | 2.335 |
| 12:32 ET | 100 | 2.34 |
| 12:39 ET | 100 | 2.34 |
| 12:41 ET | 100 | 2.33 |
| 12:52 ET | 700 | 2.32 |
| 12:57 ET | 300 | 2.32 |
| 12:59 ET | 100 | 2.33 |
| 01:15 ET | 400 | 2.32 |
| 01:19 ET | 1673 | 2.335 |
| 01:32 ET | 901 | 2.32 |
| 01:33 ET | 100 | 2.32 |
| 01:35 ET | 100 | 2.32 |
| 01:37 ET | 100 | 2.32 |
| 01:46 ET | 300 | 2.315 |
| 01:51 ET | 1100 | 2.315 |
| 01:57 ET | 100 | 2.315 |
| 02:02 ET | 100 | 2.32 |
| 02:06 ET | 300 | 2.31 |
| 02:18 ET | 100 | 2.31 |
| 02:20 ET | 560 | 2.3 |
| 02:22 ET | 218 | 2.29 |
| 02:24 ET | 300 | 2.28 |
| 02:38 ET | 7045 | 2.26 |
| 02:49 ET | 100 | 2.26 |
| 02:54 ET | 300 | 2.26 |
| 03:09 ET | 100 | 2.27 |
| 03:12 ET | 100 | 2.28 |
| 03:14 ET | 200 | 2.27 |
| 03:25 ET | 100 | 2.28 |
| 03:27 ET | 400 | 2.27 |
| 03:32 ET | 300 | 2.26 |
| 03:38 ET | 100 | 2.26 |
| 03:39 ET | 100 | 2.26 |
| 03:43 ET | 400 | 2.27 |
| 03:45 ET | 672 | 2.26 |
| 03:48 ET | 2126 | 2.24 |
| 03:50 ET | 500 | 2.23 |
| 03:52 ET | 100 | 2.24 |
| 03:54 ET | 152 | 2.2489 |
| 03:57 ET | 300 | 2.25 |
| 03:59 ET | 15841 | 2.18 |
Oct 23, 2024
DJ Generation Bio Price Target Maintained With a $10.00/Share by Needham, from 5:55AM ET on Wednesday Oct 23, 2024 by Dow Jones
5:55AM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 22, 2024
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress, from 6:59AM ET on Tuesday Oct 22, 2024 by Dow Jones
6:59AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Generation Bio Co | 156.8M | -0.9x | --- |
Adverum Biotechnologies Inc | 163.9M | -0.9x | --- |
Lineage Cell Therapeutics Inc | 160.9M | -6.2x | --- |
Vaxart Inc | 178.5M | -1.6x | --- |
Galectin Therapeutics Inc | 156.9M | -3.2x | --- |
Ventyx Biosciences Inc | 156.2M | -0.8x | --- |
Company Information
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Contact Information
- Headquarters
- 301 BINNEY STREETCAMBRIDGE, MA, United States 02142
- Phone
- 857-529-5908
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jason Rhodes
- President, Chief Executive Officer, Director
- Cameron Mcdonough
- Chief Financial Officer
- Matthew Norkunas
- Chief Operating Officer
- Antoinette Paone
- Chief Scientific Officer
- Matthew Stanton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $156.8M |
|---|---|
Revenue (TTM) | $13.2M |
Shares Outstanding | 66.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.81 |
EPS | $-2.39 |
Book Value | $3.07 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 11.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,295.89% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
